CoChat

Adverse Events Associated With PCSK 9 Inhibitors: A Real‐World Experience

Open access
Gürgöze, Muhammed T., Muller‐Hansma, Annemarie H.G., Schreuder, Michelle M., Galema‐Boers, Annette M.H., Boersma, Eric, Roeters van Lennep, Jeanine E. · 2019 · Clinical Pharmacology & Therapeutics
Cited by 92

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

In randomized clinical trials (RCT s) proprotein convertase subtilisin/kexin 9 (PCSK 9) inhibitors showed a favorable safety profile, however, “real‐world” data on adverse events (AE s) is scarce. Three datasets, a hospital registry (n = 164), and two Pharmacovigilance databases, Lareb (n = 149) and VigiLyze (n = 15,554), reporting AE s attributed to PCSK 9 inhibitors (alirocumab or evolocumab) prescribed in clinical practice were analyzed. In the hospital registry, 41.5% of the patients reported any AE, most often injection‐site reactions (33.8%) and influenza‐like illness (27.9%). Twelve patients (7%) discontinued PCSK 9 inhibitor treatment. Most common AE reported in the Lareb and VigiLyze database was myalgia (12.8% and 8.3%, respectively). No clinically relevant differences in gender or between drugs were observed. No specific subgroup of patients could be identified at risk of developing AE s. During follow‐up, AE s resolved in most patients (71.1%). In a real‐world setting, PCSK 9 inhibitors are well tolerated with an overall safety profile comparable to RCT s.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cpt.1193

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 92

Metadata

Authors
Gürgöze, M. T., Muller‐Hansma, A. H. G., Schreuder, M. M., Galema‐Boers, A. M. H., Boersma, E., & Roeters van Lennep, J. E.
Venue
Clinical Pharmacology & Therapeutics
Publisher
Wiley
Published
2018-09-07
Volume
105
Issue
2
Pages
496-504
ISSN
  • 0009-9236 (ISSN-L)
  • 1532-6535
OpenAlex
W2884577329
Cited by
92
References
12
FWCI
5.66
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.